000163868 001__ 163868
000163868 005__ 20240229133510.0
000163868 0247_ $$2doi$$a10.1007/s00405-020-06393-x
000163868 0247_ $$2pmid$$apmid:33000299
000163868 0247_ $$2ISSN$$a0937-4477
000163868 0247_ $$2ISSN$$a1434-4726
000163868 0247_ $$2altmetric$$aaltmetric:107000457
000163868 037__ $$aDKFZ-2020-02102
000163868 041__ $$aeng
000163868 082__ $$a610
000163868 1001_ $$0P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9$$aRühle, Alexander$$b0$$eFirst author
000163868 245__ $$aRadiation-induced toxicities and outcomes after radiotherapy are independent of patient age in elderly salivary gland cancer patients: results from a matched-pair analysis of a rare disease.
000163868 260__ $$aHeidelberg$$bSpringer$$c2021
000163868 3367_ $$2DRIVER$$aarticle
000163868 3367_ $$2DataCite$$aOutput Types/Journal article
000163868 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1675086828_23510
000163868 3367_ $$2BibTeX$$aARTICLE
000163868 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163868 3367_ $$00$$2EndNote$$aJournal Article
000163868 500__ $$a2021 Jul;278(7):2537-2548
000163868 520__ $$aThis study analyzed survival and toxicity after (chemo)radiotherapy for primary salivary gland cancer patients aged ≥ 65 years and compared these results with younger patients using a matched-pair analysis.Twenty-nine elderly patients with primary salivary gland carcinomas treated with (chemo)radiotherapy from 2008 to 2020 at University of Freiburg Medical Center were analyzed for oncological outcomes and therapy-associated toxicities. Local/locoregional control (LRC), progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method, and the influence of clinical parameters on patient outcomes was assessed. A matched-pair analysis was performed after matching with patients < 65 years.Nine patients (31.0%) received definitive (chemo)radiotherapy, and 20 patients (69.0%) were treated in the adjuvant setting. 2-year LRC, PFS and OS ranged at 82.4%, 53.7% and 71.8%, respectively. Smoking (HR 3.980, p = 0.020), reduced performance status (HR 3.735, p = 0.016) and higher comorbidity burden (HR 4.601, p = 0.005) correlated with inferior OS. Using a matched-pair analysis with younger patients, elderly patients exhibited a trend towards reduced OS (HR 3.015, p = 0.065), but not PFS (HR 1.474, p = 0.371) or LRC (HR 1.324, p = 0.633). Acute and chronic grade 3 toxicities occurred in 31.0% and 12.5% of elderly patients, respectively, and the matched-pair analysis revealed no significant differences between age groups regarding treatment-related toxicities.Treatment-related toxicities as well as LRC and PFS were comparable for salivary gland cancer patients undergoing radiotherapy. Therefore, concerns for more pronounced toxicities or reduced local/locoregional response rates should not guide treatment decisions in affected elderly patients.
000163868 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000163868 588__ $$aDataset connected to CrossRef, PubMed,
000163868 7001_ $$aRothhaar, Sofie$$b1
000163868 7001_ $$0P:(DE-HGF)0$$aHaehl, Erik$$b2
000163868 7001_ $$0P:(DE-HGF)0$$aKalckreuth, Tobias$$b3
000163868 7001_ $$0P:(DE-HGF)0$$aSprave, Tanja$$b4
000163868 7001_ $$0P:(DE-He78)75b4c256a6de824414938cf2aaeff88e$$aStoian, Raluca$$b5
000163868 7001_ $$0P:(DE-HGF)0$$aZamboglou, Constantinos$$b6
000163868 7001_ $$0P:(DE-HGF)0$$aGkika, Eleni$$b7
000163868 7001_ $$aKnopf, Andreas$$b8
000163868 7001_ $$0P:(DE-HGF)0$$aGrosu, Anca-Ligia$$b9
000163868 7001_ $$0P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aNicolay, Nils$$b10$$eLast author
000163868 773__ $$0PERI:(DE-600)1459042-6$$a10.1007/s00405-020-06393-x$$n7$$p2537-2548$$tEuropean archives of oto-rhino-laryngology and head & neck$$v278$$x1434-4726$$y2021
000163868 909CO $$ooai:inrepo02.dkfz.de:163868$$pVDB
000163868 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000163868 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000163868 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000163868 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000163868 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)75b4c256a6de824414938cf2aaeff88e$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000163868 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000163868 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000163868 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000163868 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000163868 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000163868 9130_ $$0G:(DE-HGF)POF3-899$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000163868 9141_ $$y2021
000163868 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2020-01-10$$wger
000163868 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2020-01-10$$wger
000163868 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR ARCH OTO-RHINO-L : 2018$$d2020-01-10
000163868 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-10
000163868 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-10
000163868 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-10
000163868 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-01-10
000163868 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-01-10
000163868 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-10
000163868 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-01-10
000163868 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-10
000163868 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-10
000163868 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-10
000163868 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-01-10
000163868 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-01-10
000163868 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-01-10
000163868 9201_ $$0I:(DE-He78)FR01-20160331$$kFR01$$lDKTK FR zentral$$x0
000163868 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x1
000163868 980__ $$ajournal
000163868 980__ $$aVDB
000163868 980__ $$aI:(DE-He78)FR01-20160331
000163868 980__ $$aI:(DE-He78)E055-20160331
000163868 980__ $$aUNRESTRICTED